Adatanserin


Adatanserin is a mixed 5-HT1A receptor partial agonist and 5-HT2A and 5-HT2C receptor antagonist. It was under development by Wyeth as an antidepressant but was ultimately not pursued.
Adantaserin has been shown to be neuroprotective against ischemia-induced glutamatergic excitotoxicity, an effect which appears to be mediated by blockade of the 5-HT2A receptor.

Synthesis

2-Chloropyrimidine reacts with piperazine, forming 2-pyrimidine. Treatment with the phthalimide derivative N-phthalimide in an alkylation reaction produces, which is deprotected using hydrazine to give the primary amine. Amide formation with the acid chloride of 1-adamantanecarboxylic acid yields adatanserin.